Dermatofibrosarcoma Protuberans Medication

Updated: Mar 06, 2020
  • Author: Raman K Madan, MD; Chief Editor: William D James, MD  more...
  • Print

Medication Summary

Although medical therapy is not a first-line treatment for localized dermatofibrosarcoma protuberans (DFSP), the approved molecular-targeted drug, imatinib mesylate, is an effective oral medication for unresectable, recurrent, and/or metastatic DFSP.


Molecular-targeted therapy

Class Summary

Before starting imatinib therapy, cytogenetic studies to confirm PDGFB gene rearrangement may be necessary for predicting the clinical response. Chromosome translocation t(17,22) is detected in more than 90% of DFSP tumors.

Imatinib mesylate (Gleevec)

Imatinib mesylate is an inhibitor of receptor tyrosine kinase for PDGF. It inhibits PDGF-B receptor-mediated cellular events, the key pathogenetic pathway in DFSP.